Is Insurf profitable in 2026?

No. Insurf is a pre-revenue, 2-person Y Combinator Summer 2026 startup with no disclosed revenue, ARR, or customers as of July 2026. Its only disclosed funding is a $500,000 convertible note, and it remains in a pre-Demo Day phase, so profitability is not yet a relevant question.

Could AI replace Insurf's own product?

Ironically yes, in part. Insurf's Inveto tool drafts appeal letters using AI, but competitor Counterforce Health published a guide (2025-11-03) showing patients can paste denial letters directly into Claude for free, undercutting the core value of paid appeal-drafting wrappers like Insurf's.

Who is Insurf's biggest competitor?

Counterforce Health is the most established rival, reporting roughly 70% claim reversal across over 10,000 appeals as of October 2025, funded by NIH and University of Pennsylvania grants rather than VC. Enterprise RCM platforms like Aspirion, Corti, and Ember also already ship appeal automation at greater scale.

Insurf is a private company backed by Y Combinator as part of its Summer 2026 (S26) batch, headquartered in San Francisco with a 2026 founding year. Its only disclosed financing is a $500,000 convertible note as of mid-2026; no institutional lead investor or named founders were confirmed in public sources.

Does Insurf have a real data moat with its coverage-decision graph?

Not yet proven. Insurf states its future product Surely will run on a 'coverage-decision graph' built from payer behavior data accumulated via Inveto, but as of July 2026 the company is pre-revenue with 2 employees and has disclosed no dataset scale or predictive validation of this claimed asset.

What is Insurf's Inveto product?

Inveto is Insurf's current AI product that automates converting denied healthcare claims into source-cited, physician-attested appeal packets, covering intake, drafting, physician review, submission, follow-up, and outcome tracking, as described on insurf.io as of July 2026. No independent effectiveness or overturn-rate data has been published.

YC Summer 2026 · United States

Insurf

Two-person YC S26 startup drafting AI health insurance appeals as a wedge into payer-data pricing.

Protection under test

Assessed 27 July 2026 · Evidence as of 27 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 27 July 2026 · Checkable from Q3-Q4 2026 · Every call on the record Checkpoint: YC Demo Day and expected Series A fundraising push

The call

Insurf is a pre-revenue two-person team entering a claims-appeal space where free chatbots and funded rivals already operate, with its long-term data plan still unproven.

Insurf uses artificial intelligence to help patients and doctors appeal denied insurance claims, hoping to collect data that reveals how insurance companies make decisions. The problem is that free AI tools like ChatGPT already do basic claim appeals, and competitors like Counterforce Health and Ember have already shipped similar products to the market. The company's real bet is whether it can gather enough real claim data before larger insurance tech companies like Optum or smaller rivals like Counterforce build the same thing first, which could happen within the next 18 to 24 months.

Why

AI pressure: Claude and ChatGPT used directly by patients and clinics to draft appeals. Counterforce Health already published a guide on using Claude to appeal denials for free, undercutting the entry point Insurf is building on. Could AI do the core job? Yes, likely.

Bigger players: Counterforce Health, Aspirion, Corti, RapidClaims, CombineHealth, Ember. These firms already run AI appeal tools at volume; Counterforce claims a 70% reversal rate across 10,000+ appeals while Insurf has none disclosed. Could a giant copy it? Yes, easily.

What protects it. None proven yet: the coverage-decision graph is a stated plan with zero disclosed volume, overturn rate, or customers.

What would change this call

Insurf publishes an overturn rate on 1,000+ Inveto appeals within 12 months. Would show Inveto works at real volume, not just as a prototype.
Insurf announces a Series A or Demo Day funding round by Q4 2026. Would show investor confidence and enough capital to compete with funded rivals.
Aspirion or Optum ships an integrated AI appeals feature at enterprise scale. Would show incumbents closing the gap before Insurf's data moat forms.

Key numbers

$500,000 raised via convertible note (2026-07-12)
2 employees listed (2026-07-22)
Counterforce Health: ~70% reversal rate, 10,000+ appeals (2025-10-10)

Named risks

Core appeal-drafting product is commoditizable by free general-purpose LLMs like Claude and ChatGPT. Severity: high
No disclosed revenue, customers, or provider logos as of July 2026 despite operating since founding. Severity: high
Claimed coverage-decision graph data moat is unproven at 2-person, pre-revenue scale. Severity: high
Multiple better-resourced or grant-backed competitors already have published outcome data and volume. Severity: medium
Pre-Demo Day funding stage means near-term dilution or failure to raise a priced round is possible. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Counterforce Health	losing to	~70% reversal rate across 10,000+ appeals reported by press as of 2025-10-10, vs Insurf's undisclosed volume
Ember Copilot	losing to	Already ships AI denial-appeal tool for athenahealth users as of 2026-06-17
Claimable	contesting	Vendor-claimed 80%+ appeal success as of 2026-07-20, targeting same consumer appeal niche
Enterprise RCM platforms (Aspirion, Corti, RapidClaims, CombineHealth)	losing to	Already serve health-system revenue-cycle teams with appeal automation at scale, per 2026-07-07 comparison
General-purpose LLMs (ChatGPT, Claude)	losing to	Patients already paste denial letters directly into Claude free per Counterforce guide, 2025-11-03
Prescience (YC S26 batch-mate)	contesting	Building full AI-native health insurance carrier targeting United and Blue Cross, launched 2026-07-21

Questions people ask

Is Insurf profitable in 2026?: No. Insurf is a pre-revenue, 2-person Y Combinator Summer 2026 startup with no disclosed revenue, ARR, or customers as of July 2026. Its only disclosed funding is a $500,000 convertible note, and it remains in a pre-Demo Day phase, so profitability is not yet a relevant question.
Could AI replace Insurf's own product?: Ironically yes, in part. Insurf's Inveto tool drafts appeal letters using AI, but competitor Counterforce Health published a guide (2025-11-03) showing patients can paste denial letters directly into Claude for free, undercutting the core value of paid appeal-drafting wrappers like Insurf's.
Who is Insurf's biggest competitor?: Counterforce Health is the most established rival, reporting roughly 70% claim reversal across over 10,000 appeals as of October 2025, funded by NIH and University of Pennsylvania grants rather than VC. Enterprise RCM platforms like Aspirion, Corti, and Ember also already ship appeal automation at greater scale.
Who owns Insurf?: Insurf is a private company backed by Y Combinator as part of its Summer 2026 (S26) batch, headquartered in San Francisco with a 2026 founding year. Its only disclosed financing is a $500,000 convertible note as of mid-2026; no institutional lead investor or named founders were confirmed in public sources.
Does Insurf have a real data moat with its coverage-decision graph?: Not yet proven. Insurf states its future product Surely will run on a 'coverage-decision graph' built from payer behavior data accumulated via Inveto, but as of July 2026 the company is pre-revenue with 2 employees and has disclosed no dataset scale or predictive validation of this claimed asset.
What is Insurf's Inveto product?: Inveto is Insurf's current AI product that automates converting denied healthcare claims into source-cited, physician-attested appeal packets, covering intake, drafting, physician review, submission, follow-up, and outcome tracking, as described on insurf.io as of July 2026. No independent effectiveness or overturn-rate data has been published.

Timeline

2026-07-22YC directory lists Insurf at 2 employees in health tech, San Francisco Bay Area
2026-07-21YC batch-mate Prescience launches, targeting United and Blue Cross directly
2026-07-20Industry guide catalogs AI appeal tools including Claimable and Fight Health Insurance
2026-07-12Insurf confirmed as Y Combinator Summer 2026 (S26) batch member, HQ San Francisco
2026-07-12CB Insights lists Insurf funding as $500,000 convertible note
2026-07-07CombineHealth publishes comparison of top 9 denial appeal platforms including RCM incumbents
2026-06-17Ember Copilot markets AI denial-appeal tool to athenahealth users
2025-11-19Employers reported bracing for largest health insurance cost increase in 15 years
2025-11-03Counterforce Health publishes guide on using Claude to appeal denied claims
2025-10-10Counterforce Health reversal-rate figures (~70%, 10,000+ appeals) covered in press

Revision history

27 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Prized Truffle Daqstra